Osvely Méndez-Guerrero

Osvely Méndez-Guerrero

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
JVJonathan Manuel Aguirre Valadez
Jonathan Manuel Aguirre Valadez
LRLiliana Rivera-Espinosa
Liliana Rivera-Espinosa
OMOsvely Méndez-Guerrero
Osvely Méndez-Guerrero
JCJuan Luis Chávez-Pacheco
Juan Luis Chávez-Pacheco
IJIgnacio García Juárez
Ignacio García Juárez
ATAldo Torre
Aldo Torre
Liver cirrhosis is a worldwide public health problem, and patients with this disease are at high risk of developing complications, bacterial translocation from the intestinal lumen to the mesenteric nodes, and systemic circulation, resulting in the development of severe complications related to high mortality rate. The intestinal barrier is a structure with a physical and biochemical activity to maintain balance between the external environment, including bacteria and their products, and the internal environment. Patients with liver cirrhosis develop a series of alterations in different components of the intestinal barrier directly associated with the severity of liver disease that finally increased intestinal permeability. A “leaky gut” is an effect produced by damaged intestinal barrier; alterations in the function of tight junction proteins are related to bacterial translocation and their products. Instead, increasing serum proinflammatory cytokines and hemodynamics modification, which results in the appearance of complications of liver cirrhosis such as hepatic encephalopathy, variceal hemorrhage, bacterial spontaneous peritonitis, and hepatorenal syndrome. The intestinal microbiota plays a fundamental role in maintaining the proper function of the intestinal barrier; bacterial overgrowth and dysbiosis are two phenomena often present in people with liver cirrhosis favoring bacterial translocation. Increased intestinal permeability has an important role in the genesis of these complications, and treating it could be the base for prevention and partial treatment of these complications.

24 February 2018 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
ARAstrid Ruiz‐Margáin
Astrid Ruiz‐Margáin
APAlessandra Pohlmann
Alessandra Pohlmann
PRPatrick Ryan
Patrick Ryan
RSRobert Schierwagen
Robert Schierwagen
LCLuis A. Chi‐Cervera
Luis A. Chi‐Cervera
JTJonel Trebicka
Jonel Trebicka

12 June 2022 in Liver International
Verified
Journal Article
Closed access
Eduardo Cervantes-AlvarezEduardo Cervantes-Alvarez
Eduardo Cervantes-Alvarez
NRNathaly Limon de la Rosa
Nathaly Limon de la Rosa
MVMario Vilatoba
Mario Vilatoba
CPCarlos Pérez‐Monter
Carlos Pérez‐Monter
SHSahara Hurtado‐Gomez
Sahara Hurtado‐Gomez
NNNalu Navarro-Alvarez
Nalu Navarro-Alvarez

21 February 2026 in Journal of Hepatology
Verified
Journal Article
Open access
CECornelius Engelmann
Cornelius Engelmann
NVNipun Verma
Nipun Verma
TQTingting Qi
Tingting Qi
AKAnnarein Johanna Catharina Kerbert
Annarein Johanna Catharina Kerbert
JPJulian Pohl
Julian Pohl
RJRajiv Jalan
Rajiv Jalan
Acute-on-chronic liver failure (ACLF) is characterised by multiorgan failure and high short-term mortality in hospitalised patients with acute decompensation of cirrhosis. Although the EASL-CLIF criteria are widely used for diagnosis and prognostication, evolving definitions of organ dysfunction and emerging therapies require updated, tailored criteria to improve diagnostic accuracy, treatment assessment, and applicability in clinical trials. We aimed to develop and validate the A-TANGO organ failure (OF) score to refine ACLF diagnosis and enhance its utility for treatment response evaluation and risk stratification. We performed a retrospective analysis of prospective observational cohorts. The derivation cohort comprised three EF-CLIF consortium studies conducted in Europe and Latin America (CANONIC, PREDICT, ACLARA; n = 3,896). Validation cohorts included one study from India (Ambi-spective study n = 2,055) and one from China (CATCH-LIFE; n = 2,568). Patients were enrolled between 2011 and 2023, with follow-up completed in 2023. The primary objective was to redefine thresholds for organ dysfunction and failure using three subscores per organ, with subscore 3 corresponding to ≥15% 28-day mortality and defining organ failure. Compared with the CLIF-C OF score, the A-TANGO OF score introduced revised thresholds for organ failure and added an ACLF grade 4 to address the wide mortality variation within CLIF-C OF grade 3. A-TANGO identified more organ failures, increasing ACLF diagnosis from 24% to 36% and improving the net reclassification index by 16%, while maintaining similar predictive accuracy for 28- and 90-day mortality. Two additional prognostic models (A-TANGO ACLF-WBC and A-TANGO ACLF-CRP) demonstrated strong associations with 28- and 90-day mortality and improved prognostic performance. Findings were confirmed in external validation cohorts. The A-TANGO OF score is a reproducible and comprehensive tool for ACLF diagnosis with preserved prognostic performance, validated across large international cohorts. It provides a robust framework for clinical trials by enabling more accurate diagnosis, reducing required sample sizes, and offering clinically meaningful endpoints such as ACLF resolution for treatment response assessment. The A-TANGO organ failure (OF) score provides a scientifically justified advancement in ACLF research by refining organ-specific dysfunction thresholds and introducing a new grade 4, thereby addressing limitations in current EASL-CLIF criteria and improving identification of high-risk patients. These findings are important for clinicians, researchers, and healthcare systems globally, as they increase detection of organ failure, enhance risk stratification, and enable more accurate prediction of short-term mortality in hospitalized patients with cirrhosis. The A-TANGO OF score and its associated prognostic scores (ACLF-WBC and ACLF-CRP) can be applied in clinical practice to guide treatment decisions, and serve as reliable, measurable endpoints in clinical trials evaluating emerging therapies. Although limitations such as missing data, cohort-specific recruitment differences, and historical classification criteria exist, the consistent and robust performance of the A-TANGO scores across large, multinational cohorts highlights their potential applicability and utility on a global scale.

1 October 2018 in Revista de Gastroenterología de México
Verified
Journal Article
Open access
ARAstrid Ruiz-Margáin
Astrid Ruiz-Margáin
OMOsvely Méndez-Guerrero
Osvely Méndez-Guerrero
BRB.M. Román-Calleja
B.M. Román-Calleja
SGS. González-Rodríguez
S. González-Rodríguez
GFG. Fernández-Del-Rivero
G. Fernández-Del-Rivero
RMR.U. Macías-Rodríguez
R.U. Macías-Rodríguez
One of the most important characteristics of malnutrition is the loss of muscle mass and the severe depletion of the protein reserve, secondarily affecting energy metabolism. That impacts nutritional status and the progression of disease-related complications. Nutritional treatment is one of the main factors in the comprehensive management of those patients. Achieving adequate energy intake that provides the macronutrients and micronutrients necessary to prevent or correct malnutrition is attempted through dietary measures. ESPEN, the European Society for Clinical Nutrition and Metabolism, recommends a caloric intake of 30-40kcal/kg/day, in which carbohydrates provide 45-60% of the daily energy intake and proteins supply 1.0-1.5g/kg/day. The remaining portion of the total energy expenditure should be covered by lipids. The administration of branched-chain amino acids has been shown to be beneficial not only in counteracting malnutrition, but also as a coadjuvant treatment in specific complications, thus playing a favorable role in outcome and quality of life. Therefore, branched-chain amino acids should be considered part of nutritional treatment in patients with advanced stages of cirrhosis of the liver, particularly in the presence of complications.

11 April 2022 in Biology
Verified
Journal Article
Open access
PDF file
NRNathaly Limon de la Rosa
Nathaly Limon de la Rosa
Eduardo Cervantes-AlvarezEduardo Cervantes-Alvarez
Eduardo Cervantes-Alvarez
OMOsvely Méndez-Guerrero
Osvely Méndez-Guerrero
MGMiguel Ángel Gutiérrez Gallardo
Miguel Ángel Gutiérrez Gallardo
DKDavid Kershenobich
David Kershenobich
NNNalu Navarro-Alvarez
Nalu Navarro-Alvarez
Independent predictors of mortality for COVID-19 patients have been identified upon hospital admission; however, how they behave after hospitalization remains unknown. The aim of this study is to identify clinical and laboratory parameters from admission to discharge or death that distinguish survivors and non-survivors of COVID-19, including those with independent ability to predict mortality. In a cohort of 266 adult patients, clinical and laboratory data were analyzed from admission and throughout hospital stay until discharge or death. Upon admission, non-survivors had significantly increased C reactive protein (CRP), neutrophil count, neutrophil to lymphocyte ratio (NLR) (p < 0.0001, each), ferritin (p < 0.001), and AST (aspartate transaminase) (p = 0.009) compared to survivors. During the hospital stay, deceased patients maintained elevated CRP (21.7 mg/dL [admission] vs. 19.3 [hospitalization], p = 0.060), ferritin, neutrophil count and NLR. Conversely, survivors showed significant reductions in CRP (15.8 mg/dL [admission] vs. 9.3 [hospitalization], p < 0.0001], ferritin, neutrophil count and NLR during hospital stay. Upon admission, elevated CRP, ferritin, and diabetes were independent predictors of mortality, as were persistently high CRP, neutrophilia, and the requirement of invasive mechanical ventilation during hospital stay. Inflammatory and clinical parameters distinguishing survivors from non-survivors upon admission changed significantly during hospital stay. These markers warrant close evaluation to monitor and predict patients’ outcome once hospitalized.